Cargando…

Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease

Despite the promising effectiveness of the coronavirus disease 2019 vaccination using an mRNA vaccine, the short efficacy duration and some poor responses to the vaccination remain major concerns. We aimed to clarify the monthly kinetics of the anti-SARS-CoV-2 spike receptor-binding domain antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugiura, Tomoko, Sugiura, Hiroaki, Kato, Hiroaki, Nariai, Yuko, Mizumoto, Yuuki, Hanada, Kozue, Takahashi, Rieko, Hinotubo, Yukari, Tanaka, Naoko, Sasaki, Mutsumi, Eguchi, Haruki, Kamino, Hiroki, Urano, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844396/
https://www.ncbi.nlm.nih.gov/pubmed/36648857
http://dx.doi.org/10.3390/idr15010003
_version_ 1784870646350610432
author Sugiura, Tomoko
Sugiura, Hiroaki
Kato, Hiroaki
Nariai, Yuko
Mizumoto, Yuuki
Hanada, Kozue
Takahashi, Rieko
Hinotubo, Yukari
Tanaka, Naoko
Sasaki, Mutsumi
Eguchi, Haruki
Kamino, Hiroki
Urano, Takeshi
author_facet Sugiura, Tomoko
Sugiura, Hiroaki
Kato, Hiroaki
Nariai, Yuko
Mizumoto, Yuuki
Hanada, Kozue
Takahashi, Rieko
Hinotubo, Yukari
Tanaka, Naoko
Sasaki, Mutsumi
Eguchi, Haruki
Kamino, Hiroki
Urano, Takeshi
author_sort Sugiura, Tomoko
collection PubMed
description Despite the promising effectiveness of the coronavirus disease 2019 vaccination using an mRNA vaccine, the short efficacy duration and some poor responses to the vaccination remain major concerns. We aimed to clarify the monthly kinetics of the anti-SARS-CoV-2 spike receptor-binding domain antibody response after two doses of the BNT162b2 vaccine in a Japanese population. A chemiluminescent enzyme immunoassay (CLIA) and an enzyme-linked immunosorbent assay were used to measure the antibody levels in 81 Japanese adults (age, <65 years). The antibody levels increased 10-fold at 2–3 weeks following the second dose of BNT162b2 and declined thereafter to approximately 50%, 20%, and 10% of the peak levels at 2, 3, and 6 months, respectively. To compare the antibody titers among different groups, older adults (age, >65 years; n = 38) and patients with systemic lupus erythematosus (SLE, n = 14) were also investigated. A decline in the mean relative antibody titers was observed in older men compared with younger men and in patients with SLE compared with individuals aged <65 years. Although the antibody levels increased drastically following two BNT162b2 doses, they then declined rapidly. Furthermore, poor responders to the vaccination were observed. Repeated vaccinations are required to maintain high antibody levels.
format Online
Article
Text
id pubmed-9844396
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98443962023-01-18 Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease Sugiura, Tomoko Sugiura, Hiroaki Kato, Hiroaki Nariai, Yuko Mizumoto, Yuuki Hanada, Kozue Takahashi, Rieko Hinotubo, Yukari Tanaka, Naoko Sasaki, Mutsumi Eguchi, Haruki Kamino, Hiroki Urano, Takeshi Infect Dis Rep Article Despite the promising effectiveness of the coronavirus disease 2019 vaccination using an mRNA vaccine, the short efficacy duration and some poor responses to the vaccination remain major concerns. We aimed to clarify the monthly kinetics of the anti-SARS-CoV-2 spike receptor-binding domain antibody response after two doses of the BNT162b2 vaccine in a Japanese population. A chemiluminescent enzyme immunoassay (CLIA) and an enzyme-linked immunosorbent assay were used to measure the antibody levels in 81 Japanese adults (age, <65 years). The antibody levels increased 10-fold at 2–3 weeks following the second dose of BNT162b2 and declined thereafter to approximately 50%, 20%, and 10% of the peak levels at 2, 3, and 6 months, respectively. To compare the antibody titers among different groups, older adults (age, >65 years; n = 38) and patients with systemic lupus erythematosus (SLE, n = 14) were also investigated. A decline in the mean relative antibody titers was observed in older men compared with younger men and in patients with SLE compared with individuals aged <65 years. Although the antibody levels increased drastically following two BNT162b2 doses, they then declined rapidly. Furthermore, poor responders to the vaccination were observed. Repeated vaccinations are required to maintain high antibody levels. MDPI 2022-12-26 /pmc/articles/PMC9844396/ /pubmed/36648857 http://dx.doi.org/10.3390/idr15010003 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sugiura, Tomoko
Sugiura, Hiroaki
Kato, Hiroaki
Nariai, Yuko
Mizumoto, Yuuki
Hanada, Kozue
Takahashi, Rieko
Hinotubo, Yukari
Tanaka, Naoko
Sasaki, Mutsumi
Eguchi, Haruki
Kamino, Hiroki
Urano, Takeshi
Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease
title Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease
title_full Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease
title_fullStr Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease
title_full_unstemmed Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease
title_short Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease
title_sort kinetics of anti-sars-cov-2 antibody response following two doses of the bnt162b2 mrna vaccine: a japanese single-center primary care clinic report involving volunteers and patients with autoimmune disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844396/
https://www.ncbi.nlm.nih.gov/pubmed/36648857
http://dx.doi.org/10.3390/idr15010003
work_keys_str_mv AT sugiuratomoko kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease
AT sugiurahiroaki kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease
AT katohiroaki kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease
AT nariaiyuko kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease
AT mizumotoyuuki kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease
AT hanadakozue kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease
AT takahashirieko kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease
AT hinotuboyukari kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease
AT tanakanaoko kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease
AT sasakimutsumi kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease
AT eguchiharuki kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease
AT kaminohiroki kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease
AT uranotakeshi kineticsofantisarscov2antibodyresponsefollowingtwodosesofthebnt162b2mrnavaccineajapanesesinglecenterprimarycareclinicreportinvolvingvolunteersandpatientswithautoimmunedisease